On February 20, we noted:
“While the obesity drug stock has already exploded, it could see higher highs. At the moment, Viking Therapeutics and its potential treatment for obesity – VK2735, has already shown a mean weight loss of up to 18 pounds from baseline. The company also initiated Phase 1 clinical study to evaluate a novel oral formulation of VK2735.”
At the time, VKTX traded at just $35 a share.
Today, it’s up to $93.53 and rocketing higher. Not only is the company emerging as a strong obesity drug contender, it may even be an acquisition target.
According to CNBC, “Some Wall Street analysts said Viking’s experimental obesity treatment may be ‘best-in-class.’ In a midstage trial, an injectable version of Viking’s drug appeared to promote even greater weight loss than Eli Lilly’s Zepbound. Analysts were particularly impressed by the weight patients lost after they took the highest dose of Viking’s drug. Those who received a weekly 15 milligram dose of the treatment lost 13.1% of their body weight on average after 13 weeks compared to those who took the placebo.”
Should VKTX see further trial success, the stock could see higher highs.
If you bought shares on our initial mention, congratulations on the win so far.
